Grace Therapeutics, Inc. (GRCE): who owns it and who trades it
As of Nov 16, 2026, GRCE insiders reported 22 purchases worth $808K in the last 12 months. The largest buyer was Opaleye Management Inc. (10% owner), with $594K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Grace Therapeutics
From the latest filingsOverall: more buying than selling. Insiders mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, GRCE insiders reported $808K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | Opaleye Management Inc. | 10% owner | Purchase | 3,087 | $1.77 | $5.5K | Form 4 |
| Nov 4, 2026 | Opaleye Management Inc. | 10% owner | Purchase | 5,027 | $1.80 | $9.1K | Form 4 |
| Nov 3, 2026 | Opaleye Management Inc. | 10% owner | Purchase | 10,328 | $1.79 | $18.5K | Form 4 |
| Oct 26, 2026 | Opaleye Management Inc. | 10% owner | Purchase | 66,411 | $1.77 | $117K | Form 4 |
| Oct 22, 2026 | Opaleye Management Inc. | 10% owner | Purchase | 21,390 | $1.93 | $41.2K | Form 4 |
| Oct 19, 2026 | Opaleye Management Inc. | 10% owner | Purchase | 4,256 | $1.88 | $8K | Form 4 |
| Oct 16, 2026 | Opaleye Management Inc. | 10% owner | Purchase | 36,347 | $1.89 | $68.8K | Form 4 |
| Oct 15, 2026 | Opaleye Management Inc. | 10% owner | Purchase | 23,485 | $1.95 | $45.7K | Form 4 |
| Oct 14, 2026 | Opaleye Management Inc. | 10% owner | Purchase | 11,233 | $1.93 | $21.7K | Form 4 |
| Oct 12, 2026 | Opaleye Management Inc. | 10% owner | Purchase | 7,215 | $2.02 | $14.6K | Form 4 |
| Oct 9, 2026 | Opaleye Management Inc. | 10% owner | Purchase | 5,340 | $2.04 | $10.9K | Form 4 |
| Oct 8, 2026 | Opaleye Management Inc. | 10% owner | Purchase | 2,077 | $2.02 | $4.2K | Form 4 |
| Oct 5, 2026 | Opaleye Management Inc. | 10% owner | Purchase | 1,694 | $2.06 | $3.5K | Form 4 |
| Oct 2, 2026 | Opaleye Management Inc. | 10% owner | Purchase | 20,000 | $2.07 | $41.4K | Form 4 |
| Oct 1, 2026 | Opaleye Management Inc. | 10% owner | Purchase | 38,796 | $2.04 | $79K | Form 4 |
| Sep 29, 2026 | Opaleye Management Inc. | 10% owner | Purchase | 7,849 | $2.09 | $16.4K | Form 4 |
| Sep 23, 2026 | Opaleye Management Inc. | 10% owner | Purchase | 5,318 | $2.10 | $11.2K | Form 4 |
| Sep 21, 2026 | Opaleye Management Inc. | 10% owner | Purchase | 9,771 | $2.10 | $20.5K | Form 4 |
| Sep 9, 2026 | Opaleye Management Inc. | 10% owner | Purchase | 5,836 | $2.09 | $12.2K | Form 4 |
| Sep 9, 2026 | Prashant Kohli | CEO | Purchase | 100,000 | $2.14 | $214K | Form 4 |
| Sep 8, 2026 | Opaleye Management Inc. | 10% owner | Purchase | 9,393 | $2.10 | $19.7K | Form 4 |
| Aug 14, 2026 | Opaleye Management Inc. | 10% owner | Purchase | 11,608 | $2.09 | $24.3K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Opaleye Management Inc. | 10% owner | $594K | – | Nov 5, 2026 |
| Prashant Kohli | Chief Executive Officer, Director | $214K | – | Sep 9, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
GRCE short interest
High short interest. 10.2% of GRCE shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 21%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.67M GRCE shares were sold short, 10.2% of the shares outstanding, down 1.0% from the report before. At the average daily volume of 135,240 shares, buying them all back would take about 12.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.67M | 10.25% | -1% | 135,240 | 12.3 |
| Oct 15, 2026 | 1.68M | 10.34% | -2% | 108,624 | 15.5 |
| Sep 30, 2026 | 1.72M | 10.58% | -3% | 90,442 | 19.0 |
| Sep 15, 2026 | 1.77M | 10.85% | +11% | 206,110 | 8.6 |
| Aug 31, 2026 | 1.59M | 9.75% | -2% | 86,742 | 18.3 |
| Aug 14, 2026 | 1.62M | 9.98% | +2% | 205,010 | 7.9 |
| Jul 31, 2026 | 1.59M | 9.77% | -3% | 280,528 | 5.7 |
| Jul 15, 2026 | 1.63M | 10.02% | -4% | 178,144 | 9.2 |
| Jun 30, 2026 | 1.71M | 10.48% | -10% | 336,901 | 5.1 |
| Jun 15, 2026 | 1.90M | 11.69% | -6% | 273,941 | 7.0 |
| May 29, 2026 | 2.02M | 13.02% | -4% | 300,478 | 6.7 |
| May 15, 2026 | 2.10M | 13.56% | -5% | 477,206 | 4.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Grace Therapeutics company events
Grace Therapeutics filed 11 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Sep 18, 2026.
- Sep 18, 2026VoteReported shareholder vote results. Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Aug 6, 2026AgreementGrace Therapeutics, Inc., in connection with a private placement offering of the Company’s common stock, par value $0.0001, entered into with certain institutional and accredited investors (i) a securities purchase agreement, and (ii) a registration rights agreement. Filing
- Jul 28, 2026AnnouncementGrace Therapeutics, Inc. issued a press release announcing receipt of the U.S. Food and Drug Administration meeting minutes from a Type A Meeting held with the FDA to discuss the Complete Response Letter issued on April 23, 2026 for the Company’s GTx-104 new drug application. Filing
- Jun 18, 2026AnnouncementGrace Therapeutics, Inc. updated its corporate presentation. Filing
- Jun 18, 2026ResultsReleased financial results. Filing
- Jun 5, 2026LeadershipGrace Therapeutics, Inc. announced that Carrie D’Andrea will cease serving as Vice President of Clinical Operations of the Company and will no longer be employed by the Company effective June 5, 2026, which was approved by the Company on June 1, 2026. Filing
- Apr 27, 2026AnnouncementGrace Therapeutics, Inc. updated its corporate presentation. Filing
- Apr 23, 2026AnnouncementGrace Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration has issued a Complete Response Letter for the Company’s New Drug Application for GTx-104 in the treatment of patients with aneurysmal subarachnoid hemorrhage. Filing
- Feb 12, 2026ResultsReleased financial results. Filing
- Jan 12, 2026LeadershipGrace Therapeutics, Inc. entered into: • an amendment to that certain Letter Agreement by and between the Company and Prashant Kohli, the Company’s Chief Executive Officer, dated August 12, 2024 (as amended on November 12, 2025 by that certain amendment, the “CEO Letter Agreement”); • an amendment… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Grace Therapeutics financials
Famous investors that hold GRCE
2 of the 50 well-known investors we track reported holding GRCE in their latest 13F filing. The largest position is Jim Simons's, worth $400K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 186,134 | $400K | 0.0% | New |
| Ken Griffin · Citadel Advisors | Q3 2026 | 66,696 | $143K | 0.0% | -81% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named GRCE in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | ADAR1 Capital Management, LLC | 13G/A | 9.9% |
| Nov 16, 2026 | ADAR1 Capital Management, LLC | 13G/A | 9.9% |
| Nov 13, 2026 | Nantahala Capital Management, LLC | 13G/A | 7.5% |
| Nov 13, 2026 | Nantahala Capital Management, LLC | 13G/A | 7.5% |
Questions about Grace Therapeutics, Inc. (GRCE) stock
Are GRCE insiders buying or selling?
In the last 12 months, GRCE insiders reported 22 open-market purchases worth $808K and no sales. The latest trade was on Nov 5, 2026. See every trade.
What is the short interest in GRCE?
As of Oct 30, 2026, 1.67M GRCE shares were sold short, 10.2% of the shares outstanding, down 1.0% from the report before. At the average daily volume of 135,240 shares, buying them all back would take about 12.3 trading days (days to cover). See the history.
Which famous investors hold GRCE?
2 of the 50 well-known investors we track reported GRCE in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $400K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.